Plasmonics, Год журнала: 2025, Номер unknown
Опубликована: Март 31, 2025
Язык: Английский
Life, Год журнала: 2025, Номер 15(2), С. 138 - 138
Опубликована: Янв. 21, 2025
Lung cancer remains the leading cause of cancer-related mortality worldwide, characterized by its complexity and heterogeneity [...]
Язык: Английский
Процитировано
1
Cancer Cell International, Год журнала: 2025, Номер 25(1)
Опубликована: Март 1, 2025
At present, there is no effective prognostic indicator for muscle invasive bladder cancer (MIBC). A liquid biopsy method, plasma circulating tumor DNA (ctDNA) detection, was evaluated use in predicting the prognosis of different cancers. This study aims to assess value ctDNA state muscle-invasive patients. We comprehensively searched three public databases (PubMed, EMBASE, and Cochrane Library) December 2023 according Preferred Reporting Items Systematic Review Meta-analysis (PRISMA) statement. Studies investigating outcome indicators patients with MIBC were included our analysis. The hazard ratios (HRs) 95% confidence intervals (CIs) extracted evaluate association between MIBC. Eleven studies 1,170 diagnosed cancer, comprising a total four retrospective cohort eight prospective studies, meta-analysis, one which had two cohorts. analysis revealed that positive associated poor overall survival (OS), progression-free (PFS), recurrence-free (RFS) (HR = 4.51, CI: 2.64–7.69, P < 0.001; HR 4.50, 2.77–7.30, 6.56, 4.18–10.30, 0.001), significant effects both pre- post-treatment. In addition, longitudinal proved be monitoring receiving treatments 0.24, 0.14–0.41, 0.001). OS, PFS, RFS Meanwhile, clearance improved These findings suggest predictive MIBC, can used monitor recurrence guide treatment. Thus, level detection shows potential treatment
Язык: Английский
Процитировано
1
Biomarker Research, Год журнала: 2025, Номер 13(1)
Опубликована: Март 7, 2025
Abstract Developing accurate, clinically convenient, and non-invasive methods for early cancer detection, monitoring, prognosis assessment is essential improving patient survival rates, enhancing quality of life, reducing the socioeconomic burden associated with cancer. This goal critical in precision oncology. Genetic epigenetic alterations circulating cell-free DNA (cfDNA) have emerged as transformative tools advancing outcomes. Among these, 5-hydroxymethylcytosine (5hmC) modifications cfDNA stand out promising markers, offering insights into initiation, progression, metastasis, across various types, such lung cancer, colorectal hepatocellular carcinoma. review comprehensively explores biology sequencing methodologies 5hmC, emphasizing their potential screening, diagnosis, treatment prognostic assessment. It highlights recent advancements cfDNA-derived 5hmC signatures’ applications, addressing strengths limitations context clinical translation. Furthermore, this outlines key challenges future directions integrating routine practice, facilitating personalized management.
Язык: Английский
Процитировано
1
Japanese Journal of Clinical Oncology, Год журнала: 2025, Номер unknown
Опубликована: Март 13, 2025
Abstract Precision medicine based on biomarkers, such as genetic abnormalities and PD-L1 expression, has been established for the treatment of nonsmall cell lung cancer. Recently, liquid biopsy emerged a valuable minimally invasive alternative. This method analyzes blood other bodily fluids to detect cancer-related molecular residual disease (MRD). Liquid biopsy, which includes testing circulating tumor cells, DNA (ctDNA), microRNA (miRNA), offers several advantages over conventional methods. It is invasive, can be performed repeatedly, provides crucial information early cancer diagnosis, genotyping, monitoring. Elevated ctDNA levels miRNA markers show promise diagnosis. complements traditional tissue during particularly when samples are insufficient. Tests Cobas® EGFR Mutation Test v2 Guardant360® CDx have shown effective in detecting mutations guiding decisions. Although accuracy still lower than that its clinical utility continues improve. For prediction recurrence monitoring, analysis MRD earlier imaging, offering potential benefits adjustment relapse detection. The continuous development validation methods essential improving personalized strategies.
Язык: Английский
Процитировано
1
Cancers, Год журнала: 2025, Номер 17(2), С. 326 - 326
Опубликована: Янв. 20, 2025
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification RCC primarily based on distinct morphological and molecular characteristics, with two broad categories: clear (ccRCC) non-clear (nccRCC). Clear predominant subtype, representing about 70–80% all cases, while subtypes collectively make up remaining 20–30%. Non-clear encompasses many histopathological variants, each unique biological clinical characteristics. Additionally, any subtype can undergo sarcomatoid dedifferentiation, which associated poor prognosis rapid progression. Recent advances in profiling have also led to identification molecularly defined further highlighting complexity this disease. While immunotherapy has shown efficacy some variants subpopulations, significant gaps remain treatment rare subtypes. This review explores outcomes across subtypes, including highlights opportunities for improving care through novel therapies, biomarker-driven approaches, inclusive trial designs.
Язык: Английский
Процитировано
0
Journal of Gastrointestinal Surgery, Год журнала: 2025, Номер unknown, С. 101976 - 101976
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Seminars in Immunopathology, Год журнала: 2025, Номер 47(1)
Опубликована: Фев. 1, 2025
Abstract Tumors constantly shed cancer cells that are considered the mediators of metastasis via blood stream. Analysis circulating and cell-free DNA (cfDNA) in liquid biopsies, mostly taken from peripheral blood, have emerged as powerful biomarkers oncology, they enable detection genomic aberrations. Similarly, biopsies pregnant women serve prenatal screening test for an abnormal number chromosomes fetus, e.g., analysis microchimeric fetal cfDNA maternal blood. Liquid minimally invasive and, consequently, associated with reduced risks patients. However, different challenges arise oncology pregnancy-acquired regard to analyte concentration biological (background) noise among other factors. In this review, we highlight unique properties tumor (CTC), summarize various techniques been developed enrichment, CTCs well genetic epigenetic aberrations range possible clinical applications. Lastly, potential, but also their translational value microchimerism discussed.
Язык: Английский
Процитировано
0
Journal of Controlled Release, Год журнала: 2025, Номер 380, С. 269 - 282
Опубликована: Фев. 6, 2025
Язык: Английский
Процитировано
0
Cancer Letters, Год журнала: 2025, Номер unknown, С. 217531 - 217531
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Extracellular Vesicles and Circulating Nucleic Acids, Год журнала: 2025, Номер 6(1), С. 112 - 27
Опубликована: Фев. 24, 2025
The role of extracellular vesicles (EVs) in mediating chemoresistance has gained significant attention due to their ability transfer bioactive molecules between drug-resistant and drug-sensitive cells. In particular, they have been demonstrated play an active part breast cancer by the horizontal genetic protein material. This review highlights EVs, particularly miRNA cargo, driving drug resistance cancer. EVs derived from chemoresistant cells carry miRNAs lncRNAs, which are known modulate gene networks involved cell proliferation survival. These cargo suppress apoptosis targeting pro-apoptotic genes like PTEN BIM, promote epithelial-mesenchymal transition (EMT) through regulation pathways such as TGF-β Wnt/b-catenin, contribute tumor growth enhancing angiogenesis modulating microenvironment. Beyond RNA-mediated effects, also functional proteins, including P-glycoprotein Hsp70, impact cellular metabolism survival pathways. Our findings underscore significance chemoresistance, suggesting potential involvement possible prognostic factors predict therapy response therapeutic targets combination with usual therapy.
Язык: Английский
Процитировано
0